Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000806274 | SCV000946263 | pathogenic | Wilson disease | 2023-06-12 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Pro767 amino acid residue in ATP7B. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 29085216). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATP7B protein function. ClinVar contains an entry for this variant (Variation ID: 651012). This missense change has been observed in individual(s) with Wilson disease (PMID: 25497208). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs776668666, gnomAD 0.008%). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 767 of the ATP7B protein (p.Pro767Leu). |
Genome- |
RCV000806274 | SCV001977333 | likely pathogenic | Wilson disease | 2021-08-10 | criteria provided, single submitter | clinical testing | |
Ai |
RCV002223947 | SCV002502271 | likely pathogenic | not provided | 2022-03-21 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000806274 | SCV004845546 | likely pathogenic | Wilson disease | 2024-02-05 | criteria provided, single submitter | clinical testing | This missense variant replaces proline with leucine at codon 767 of the ATP7B protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Although functional studies have not been reported for this variant, it alters a conserved proline residue in the transmembrane domain M4 of the ATP7B protein (a.a. 764 - 784), a highly conserved region that is considered to be important for ATP7B protein function (PMID: 35245129; ClinVar). This variant has been observed in the compound heterozygous state with a pathogenic variant in the same gene in an individual affected with autosomal recessive Wilson disease (PMID: 25497208), indicating that this variant contributes to disease. This variant has been identified in 3/280964 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. |
Fulgent Genetics, |
RCV000806274 | SCV005636197 | likely pathogenic | Wilson disease | 2024-04-30 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000806274 | SCV001463838 | uncertain significance | Wilson disease | 2020-09-16 | no assertion criteria provided | clinical testing |